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Background: Novel approaches to reduce diabetic foot ulcers (DFU) in 
low- and middle-income countries are needed. Our objective was to 
compare incidence of DFUs in the thermometry plus mobile health 
(mHealth) reminders (intervention) vs. thermometry-only (control). 
Methods: We conducted a randomized trial enrolling adults with type 
2 diabetes mellitus at risk of foot ulcers (risk groups 2 or 3) but 
without foot ulcers at the time of recruitment, and allocating them to 
control (instruction to use a liquid crystal-based foot thermometer 
daily) or intervention (same instruction supplemented with text and 
voice messages with reminders to use the device and messages to 
promote foot care) groups, and followed for 18 months. The primary 
outcome was time to occurrence of DFU. A process evaluation was 
also conducted. 
Results: A total of 172 patients (63% women, mean age 61 years) were 
enrolled; 86 to each study group. More patients enrolled in the 
intervention arm had a history of previous DFU (66% vs. 48%). Follow-
up for the primary endpoint was complete for 158 of 172 participants 
(92%). Adherence to ≥80% of daily temperature measurements was 
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87% (103 of 118) among the study participants who returned the 
logbook. DFU cumulative incidence was 24% (19 of 79) in the 
intervention arm and 11% (9 of 79) in the control arm. After adjusting 
for history of foot ulceration and study site, the hazard ratio (HR) for 
DFU was 1.44 (95% CI 0.65, 3.22). 
Conclusions: In our study, conducted in a low-income setting, the 
addition of mHealth to foot thermometry was not effective in reducing 
foot ulceration. Importantly, there was a higher rate of previous DFU 
in the intervention group, the adherence to thermometry was high, 
and the expected rates of DFU used in our sample size calculations 
were not met. 
Trial registration: ClinicalTrials.gov NCT02373592 (27/02/2015)
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Background
The prevalence of type 2 diabetes mellitus in the adult population 
worldwide has doubled from 4.7% in 1980 to 8.5% in 20141. 
Low- and middle-income countries (LMICs) are disproportion-
ally affected by diabetes, since diabetes-related complications, 
such as diabetic foot ulcer (DFU), are more frequent in these 
contexts1,2. In the US, 60%–70% of people with diabetes will 
develop peripheral neuropathy3. This is important since one in 
four patients with peripheral neuropathy will develop a DFU, 
which will increase the risk of foot amputation significantly4.
Thermometry is a tool that can identify early signs of foot inflam-
mation, thus providing early signals to enact management and 
reduce the incidence of DFU and amputation5. Three previous 
clinical trials6–8 and one systematic review have found that the use 
of thermometry reduced DFU incidence four- to ten-fold among 
individuals with diabetes at high-risk of developing a DFU9. 
Additionally, one study found that the addition of counselling to 
promote self-monitoring of skin temperature to standard care 
is feasible10. However, the benefits of thermometry depend on 
patient adherence to self-assessment, and foot temperature should 
be evaluated on at least half of the days to effectively reduce 
the risk of foot ulceration7. Yet, adherence could be challeng-
ing, especially in LMIC settings. Therefore, novel approaches to 
improve self-management thermometry adherence are needed. In 
this context, interventions using short message service (SMS) for 
diabetes management have been found to be useful to improve 
self-efficacy, social support11, and clinical diabetes-related 
outcomes12.
Other approaches that could prevent foot ulcers include patient’s 
foot self-care behaviour, annual foot evaluations, knowledge 
about diabetic foot in health care workers, and therapeutic 
footwear13. Also, in order to prevent recurrent ulcers, it is 
important to consider the integration or combination of these 
approaches14.
We propose to evaluate the efficacy of a combination of foot 
thermometry plus mobile health (mHealth)-delivered reminders, 
using SMS and voice messaging, in reducing DFU in Peru. Our 
objective was to compare incidence of DFU in the thermometry 




This was a physician- and evaluator-blinded, 18-month, rand-
omized clinical trial with two parallel arms and a 1:1 allocation. 
Details of the intervention and the study protocol have been 
published elsewhere15. We followed the extension of the 
CONSORT 2010 statement for reporting pragmatic trials16.
Although initially planned to follow participants for 12 months, 
we decided to extent the follow-up period to 18 months to 
accrue enough DFU events, as we noticed that the frequency of 
DFU at six months was lower than we expected. Thus, only the 
extension of the trial follow-up was changed without affecting 
randomization or assessment rates. There were no other 
deviations from the original trial protocol.
Participants
Participants were recruited at the outpatient clinics of two 
third-level public hospitals in Lima, Peru; Hospital Nacional 
Cayetano Heredia and Hospital Nacional Arzobispo Loayza. 
In some cases, physicians referred the patient to the study 
fieldworkers to perform a foot evaluation and in other cases 
fieldworkers conducted an active search for potential participants 
in the waiting room of the Endocrinology clinic.
Patients were eligible if they: had a diagnosis of type 2 diabe-
tes mellitus; were between 18 and 80 years of age; were in risk 
group 2 or 3 using the diabetic foot risk classification system as 
specified by the International Working Group on the Diabetic 
Foot ([IWGDF], neuropathy and deformity = category 2, history 
of ulcer and/or amputation = category 3)17–19; had a palpable 
dorsalis pedis pulse in both feet; had an operating cell phone or 
a caregiver with an operating cell phone; and had the ability to 
provide informed consent. Patients were considered not eligible 
if they had current foot ulcers, active Charcot osteoarthropathy, 
severe peripheral arterial disease, or foot infection.
Our eligibility criteria used IWGDF categories and included 
people with diabetes at risk of ulceration group 2 and 3. In so 
doing, rather than focusing only on those at the highest risk for 
ulceration (IWGDF group 3) we wanted to pursue a prag-
matic approach for the prevention of DFU among people with 
diabetes, thus including also those participants from the 
IWGDF group 2 category. All previous studies included mostly 
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participants from IWGDF group 3, and only one clinical trial 
included group 2 patients.
Development and validation of mHealth messages
The content of the mHealth messages was developed and 
validated with 19 people with type 2 diabetes mellitus. Messages 
were tested using short open surveys to evaluate the clarity 
and appropriateness of the messages. These messages were 
constructed based on a literature review about the characteristics 
of health education messages, paired with the advice from a 
specialist in health communication, taking into consideration the 
reading level of our population and the use of short messages 
focused on a single idea. We also asked colleagues with pre-
vious experience on the use of SMS and mHealth to review the 
messages before testing them with patients, and changes were 
introduced after their revision.
We printed all the messages in a single page which was 
provided to the participants to read by himself/herself. After-
wards, we evaluated each message using the following six 
questions: (1) Is the message clear?, (2) Could you tell me how 
would you explain the content of the message to another 
person?, (3) Is there any word(s) that is difficult to understand?, 
(4) Is there something that you do not like about the message?, 
(5) Is there any suggestion to improve the message?, and 
(6) Would you prefer to be addressed in a formal way “usted” 
or an informal way “tu”? (see Extended data20).
Interventions
At the initiation visit, all participants received education about 
foot care, i.e. etiology and risk factors for the development of 
neuropathy and ulcers, as well as recommendations for foot 
care practices and early signs of ulceration; and instructions for 
the use of the TempStat™ device (see Extended data). This 
foot care education was done through three videos that were 
validated by physicians and patients with type 2 diabetes mel-
litus. The first two videos lasted 8 and 6 minutes and they were 
related to foot care, whereas the third video lasted 6 minutes and 
presented the instructions on the use of the TempStat™ device. 
The three videos were in Spanish and were showed once at the 
initiation visit, as detailed elsewhere15. The device uses liquid 
crystal technology to provide a visual image of the temperatures 
(e.g. yellow image represents a higher temperature than blue 
image) (Figure 1). Frykberg et al.21 showed that TempStat™ can 
detect alarm signs, represented by a yellow color change, and 
the results positively correlate to temperature findings of infrared 
thermometer, the gold standard of thermometry devices. Another 
study found that the device identified 74% of serious foot 
problems22.
One week after enrollment, the TempStat™ was provided to each 
participant. Fieldworkers instructed the participants to use the 
device daily and to contact them by phone or SMS if one of the 
alarm signs appeared in the pads of the TempStat™: two differ-
ent colors in the contralateral areas of the feet or a yellow spot 
in any area for two consecutive days. In these cases, the nurse 
asked about any lesions in the feet as well as the participant’s 
activity in the last two weeks and provided recommendations on 
how to decrease activity until foot temperature normalized. Also, 
in cases where the alarm sign persisted more than one week, 
an in-person evaluation was performed to assess the patient 
for infection and/or a masked injury. Additionally, partici-
pants were trained to contact the study nurse in cases of dermal 
lesion of the foot and they were asked to be evaluated promptly 
by a nurse who was blind to the intervention. When a DFU was 
confirmed, the study nurse referred the patients to follow the 
standard protocol.
In the intervention arm, in addition to the TempStat™, par-
ticipants received the mHealth component weekly (two 
reminder messages and six foot-care promotion messages each 
week) for the 18-month study period via both SMS and voice 
messaging. 
Developed and validated messages23 were sent at 8am approxi-
mately and, for the first two weeks of the intervention, daily 
(Monday to Friday) reminders to use the TempStat™ were sent. 
Thereafter, for the remaining 76 weeks, patients received only 
two messages per week at the same time: the content alternating 
Figure 1. TempStat. A) Normal appearance. B) Alarm sign (yellow spot). Source: Visual Footcare Technologies LLC ©, 2013.
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between reminders to use the TempStat™ and promotion of 
foot care (one SMS and one voice message). Messages were 
delivered to the participant or caregiver’s cell phones through 
an automated software system developed by the study team (see 
Software availability24). Every week the system was evaluated 
by the study coordinator to verify its functionality.
Study procedures
At baseline, enrolled participants provided information to the 
fieldworker through questionnaires on lifestyle, history of cardio-
vascular disease and diabetes, current diabetes treatment, use of 
insoles, use of orthopedic shoes and mobile phone literacy and 
underwent a demographic evaluation (age, gender, educational 
level), socioeconomic evaluation (working status), depression 
assessment (Patient Health Questionnaire-9), anthropometric 
evaluation (weight, height and body mass index) and blood 
pressure measurements (see Extended data25).
Periodic assessments of the participants involving a general 
checkup and lower extremity evaluation was conducted every 
two months by the nurse evaluator. Additionally, the nurse col-
lected data about diabetes treatment, caregiver presence, use 
of insoles and/or orthopedic shoes, and had their weight and 
blood pressure measured (Extended data25). In some cases, 
participants could not attend to the hospital for the checkup; 
in those cases, we completed the visit by phone or by domicili-
ary visits. In the last visit at 18 months, participants were asked 
to return their logbook of temperature measurements. In gen-
eral, participants were encouraged to maintain regular visits 
with their treating  physician in the outpatient clinic.
Glycated hemoglobin (HbA1c) was measured at baseline, six, 
12 and 18 months. Measurements at baseline and 18 months 
were used for the study and measurements at six and 12 months 
were for standard of care. HbA1c was measured using high-
performance liquid chromatography (D10, BioRad, Munich, 
Germany). The blood sample was collected in the endocrinology 
clinic by the nurse evaluator during the periodic assessment 
at the time periods specify above. All samples were trans-
ported to be analyzed in a single facility and were checked with 
regular external standards and internal duplicate assays and 
monitored by BioRad for quality control.
Outcomes
The primary outcome was DFU. The definition was based on 
the American Diabetes Association criteria26,27 and for this study 
it was considered as the presence of DFU occurring at any point 
during the 18-month study period after randomization. The eval-
uator was a trained nurse blind to the intervention allocation. 
The identification of a DFU was through three ways: during the 
bimonthly clinical nurse evaluations; if an alarm sign had been 
noted and prompted the participant to seek clinical evaluation; 
or if the participant identifies a dermal lesion and seeks clinical 
evaluation.
The following were pre-defined as secondary outcomes: adher-
ence to daily temperature measurement, defined as the partici-
pants having recorded their temperature measurements in the 
logbook on ≥80% of days, and ≥1% reduction in HbA1c when 
comparing the 18-month with baseline values. Another outcome 
was alarm signs registered in the logbook.
Our protocol15 considered one additional pre-defined second-
ary outcomes: frequency of alarm signs reported to the study 
nurse. This was not analyzed because of their low frequency. 
The dose-response analysis of SMS and voice messaging, 
pre-specified as a secondary outcome in the protocol, was 
included as part of the process evaluation.
Sub-group analyses
Our a priori sub-group analyses were i) previous foot ulcera-
tion and ii) caregiving status, considering assistance provided 
to the patient with basic activities of daily living, or in the iden-
tification, prevention, or treatment of diabetes or any disability. 
Also, within the intervention-arm only, the type of recipi-
ent of the messaging (patient vs. caregivers) was considered 
for sub-group analyses. In our protocol15, we also consid-
ered sub-group analyses of participants that use insoles and/or 
orthopedic shoes, but these were not analyzed due to low fre-
quency.
Sample size
The sample size was estimated using data from previous ran-
domized trials in study populations similar to our study 
population7,8. We expected an absolute change of 21% between 
the intervention arm and the control arm (9% vs 30%) and with 
a power of 0.9 and an alpha of 0.05, we required a sample size 
of 78 participants. We planned to enroll 86 participants in each 
study arm, anticipating a 10% dropout rate.
Randomization
We conducted stratification using the hospital site as a sin-
gle stratum and blocks of 6 to generate a random allocation 
sequence. Sealed envelopes with codes to randomize participants 
were used. An independent researcher prepared the envelopes, 
and the study nurses assigned the codes to each of the enrolled 
participants. Separately, the study coordinator was responsi-
ble for opening the envelopes and informing participants about 
their intervention or control allocation as per the random list. 
The nurse/independent evaluators were not aware of the 
patient’s group allocation.
Blinding
The participants were instructed not to discuss their treatment 
assignment with the blinded evaluator. Physicians providing 
care to study participants, nurses and the field coordinators 
were blind to treatment allocation.
Process evaluation
Additionally, we performed a process evaluation during the 
18-month follow-up visit to a random group of participants of 
the two study sites. We obtained information through a set of 
questions and direct observation of the use of the TempStat™ 
with 102 participants. In addition, with 39 participants, we 
asked close and open questions about the messages received in 
the week prior to the 18-month follow-up visit. As part of this 
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process evaluation, we aimed to know: i) if participants knew 
how to use the TempStat™; ii) how many SMS and voice mes-
sages were delivered by the automated system to study partici-
pants according to the automated system; iii) how many SMS 
and voice messages were received by study participants accord-
ing to the automated system; iv) if participants understood the 
messages (only if participants reported that they had received 
a message in the previous two weeks); and v) opinions from 
the participants about their preferences in SMS vs. voice 
messages.
The process evaluation was performed by two fieldworkers 
different to those who delivered the intervention and data 
collection was conducted through observation (participants were 
asked to show how they used the TempStat™), questionnaire 
(about nursing consultation, report of communication with study 
nurses, reasons for communication, alarm sign detection) and open 
questions (related to SMS or voice messaging preferences, use of 
TempStat™, suggestions about how to improve the intervention)25.
Statistical methods
To compare the rates of DFU between study arms we performed 
a time-to-event approximation using Cox’s regression, having 
time to DFU at 18 months as an outcome. Hazard ratios (HR) 
and their respective 95% confidence intervals (95% CI) were 
estimated for the primary outcome of DFU and for the a priori 
defined sub-group analyses. These analyses included all retained 
participants, regardless of the number of visits attended, fol-
lowing the intention-to-treat principle. The model was adjusted 
by site and history of previous ulcer. Evaluation of secondary 
outcomes of interest was performed using logistic regres-
sion analysis to calculate odds ratios (OR) and 95% CI. Data 
analysis was conducted in STATA V.14.0 (StataCorp, College 
Station, TX, USA).
For the process evaluation, frequencies and percentages are 
presented. Also, open-ended questions were transcribed, and 
then a codebook was created, themes were derived from the 
data. Coding was performed manually and patterns of answers 
are described.
Ethics
The study protocol, informed consent templates, and ques-
tionnaires were reviewed and approved by the Institutional 
Review Board (IRB) at Universidad Peruana Cayetano Heredia 
(UPCH) in Lima, Peru (SIDISI 61482). In addition, participating 
hospitals (Hospital Cayetano Heredia and Hospital Nacional 
Arzobispo Loayza) in the study received the protocol and 
consent form for approval16. The extension in the follow-up 
period was also approved by the IRB at UPCH and the par-
ticipants re-consented. The fieldworker explained the study 
procedures, then the potential participant read the informed con-
sent form and asked questions. After that, if they accepted, they 
signed the informed consent form. The trial was registered at 
ClinicalTrials.gov with the identifier NCT02373592 (27/02/2015).
Results
The recruitment was conducted between October 2015 and 
March 2016 and the follow-up period lasted until October 2017.
In total, 416 participants were screened and 214 were eligible for 
the study. Of these, 192 gave informed consent and 172 attended 
the initiation visit and were allocated to the control (n=86) 
or intervention (n=86) arms (Figure 2). Only 79/86 (91.9%) 
participants in each arm completed the 18-month follow-up. 
Reasons for lost to follow-up included migration back to the 
participant’s place of origin, wrong/incomplete addresses pro-
vided, or the participant did not answer the contact phone 
calls.
Baseline characteristics
The baseline characteristics were similar between the inter-
vention and control arms, with few exceptions (Table 1). His-
tory of previous foot ulcers was reported with more frequency 
in the intervention arm; 65.9% vs. 48.2% in the control arm 
(p-value 0.02). Mean HbA1c was 8.9% in the intervention 
arm and 8.2% among the controls (p-value 0.03). In terms of 
mHealth literacy, there were no major differences between study 
arms, with the exception that participants in the intervention arm 
reported more frequently never having problems with cellphone 
coverage (89.5% vs. 74.4% in the control arm, p-value 0.01).
Primary outcome
The cumulative incidence of DFU in the entire sample was 
17.7% (28/158), and it was higher among participants with a 
history of previous ulceration (27.8%, 25/90)28.
The incidence of DFU was 11.4% (95% CI 5.2% – 21.6%) in 
the control arm and 24.1% (95% CI 14.5% – 37.6%) in the inter-
vention arm. Compared to the thermometry-only control arm, 
the adjusted hazard ratio (aHR) of DFU in the thermometry + 
mHealth intervention arm adjusted by site was 2.12 (95% CI 
0.96 – 4.68), and 1.44 (95% CI 0.65 – 3.22) adjusted by site and 
previous foot ulceration (Table 2). The incidence of DFU in par-
ticipants with previous foot ulceration was 23.7% (9/38) in the 
control arm and 30.8% (16/52) in the intervention arm, whereas 
in the participants without previous foot ulceration, incidence 
was 0% (0/38) in the control arm and 7.7% (2/26) in the inter-
vention arm. Four participants did not have information related 
to their previous foot ulceration status (three from the control 
arm and one from the intervention arm).
Secondary outcomes
The frequency of ≥80% of adherence to daily temperature 
measurement was 87.2% (103/118) among the study partici-
pants that returned the logbook. There was no evidence of a 
difference between study arms in the secondary outcomes of 
adherence to daily temperature measurements or reduction of 
HbA1c (Table 2). Also, we found that 41% of the participants 
recorded an alarm sign in their logbooks. Additionally, 67% 
of the participants that presented an ulcer also reported an 
alarm sign in their logbook.
Sub-group analyses in intervention vs. control arms
No effects of the intervention were found according to a priori 
pre-defined sub-groups. Among participants that did not have 
a caregiver (n=96), the aHR of developing a DFU was 3.34 
(95% CI 0.94 – 11.92), adjusted by site and previous ulcer. 
Other results for sub-group analyses are shown in Table 3.
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Figure 2. Flowchart.
Sub-group analysis within the intervention arm
Participants were arranged according to the recipient of the 
mHealth reminders; the participants themselves (45/86) or the 
caregiver (41/86). We found no evidence of a difference in 
DFU incidence between these two groups in crude (HR 1.09, 
95% CI 0.44 – 2.70), and adjusted analyses (aHR 1.72, 95% 
CI 0.65 – 4.54, adjusted by site and previous ulcer).
Process evaluation indicators
Some process evaluation indicators for TempStat™ use and under-
standing of the messages are shown in Table 4 and Table 5. This 
data was obtained at the 18-month follow-up visit29,30.
Dose of the mHealth component. The total number of mes-
sages to be sent to the patients in the intervention group during 
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      Site 1 53 (61.6) 53 (61.6)
      Site 2 33 (38.4) 33 (38.4)
Sociodemographic variables 
      Age, mean (SD)* 62.1 (9.8) 60.3 (9.2)
      Sex (female) 56 (65.1) 52 (60.5)
      Level of education
             <7 years 30 (34.9) 30 (34.9)
             7 to 11 years 40 (46.5) 42 (48.8)
             12 or more years 16 (18.6) 14 (16.3)
      Marital status: married or 
cohabitant
63 (73.3) 59 (68.6)
      Currently working 34 (39.5) 33 (38.4)
      Had a caregiver 35 (40.7) 36 (41.9)
Clinical variables 
      Body mass index, mean 
(SD)
27.9 (4.8) 28.0 (4.4)
      Depression (>9 points in 
PHQ-9)
23 (27.1) 22 (25.6)
      Co-morbidities
             Hypertension 
diagnosis
37 (43.0) 41 (47.7)
             Previous myocardial 
infarction
3 (3.5) 4 (4.7)
             Other cardiac 
problems
3 (3.5) 3 (3.5)
             Previous stroke 3 (3.5) 5 (5.8)
             High cholesterol 48 (55.8) 41 (47.7)
Behavioral variables
      Current smoker (self-
reported)
4 (4.7) 11 (12.9)
      Binge drinking at least 
once during the last year
28 (32.6) 20 (23.3)
      Physical activity 
(moderate/vigorous, three or 
more days a week)
7 (8.2) 13 (15.3)
Variables related to 
diabetes 
      Years since diabetes 
diagnosis, mean (SD)*






      HbA1c at baseline %, 
mean (SD)
8.2 (1.9) 8.9 (2.3)
      Current pharmacological 
treatment for diabetes
             Metformin 67 (77.9) 72 (83.7)
             Insulin 35 (40.7) 47 (54.7)
      Consultations in the last 
12 months
             Ophthalmology 48 (56.5) 45 (52.3)
             Nephrology 16 (18.6) 21 (24.4)
             Cardiology 30 (35.7) 35 (41.2)
      Complications
             Diabetic retinopathy 13 (15.3) 21 (24.4)
             Diabetic nephropathy 5 (6.0) 9 (10.6)
      Hospitalization in the last 
year due to diabetes
10 (11.6) 9 (10.5)
      Current use of orthopedic 
shoes**
0 (0) 4 (4.7)
      Current use of insoles** 2 (2.3) 8 (9.3)
mHealth literacy 
      The patient receives 
messages (instead than the 
caregiver)
45 (52.3) 45 (52.3)
      The patient knows how to 
make calls**
81 (96.4) 85 (98.8)
      The patient knows how to 
answer to calls**
82 (97.6) 85 (100.0)
      The patient knows how to 
send SMS
77 (91.7) 75 (89.3)
      The patient knows how to 
read SMS**
82 (97.6) 78 (91.8)
      Never have problems 
with cellphone coverage
61 (74.4) 77 (89.5)
Foot examination 
      Previous foot ulcers 40 (48.2) 56 (65.9)
      Previous foot amputation 10 (12.1) 14 (16.5)
      Any deformity in foot 53 (63.9) 54 (63.5)
      Any alteration in 
monophilament test
71 (85.5) 70 (82.4)
      Any alteration in 
biotensiometer (≥25)
65 (78.3) 75 (88.2)
* T-test; **Fisher’s exact text.
SD, standard deviation; PHQ, patient health questionnaire; mHealth, mobile 
health; SMS, short message service.
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n/N (%) n/N (%) HR (95% CI) OR (95% CI)
Primary outcome: DFU
      Overall population 9/79 (11.4) 19/79 (24.1)
             Adjusted by site 2.12 (0.96 – 4.68) --
             Adjusted by previous foot ulceration 1.47 (0.66 – 3.30) --
             Adjusted by site and previous foot 
ulceration 1.44 (0.65 – 3.22) --
Secondary outcomes
≥80% daily temperature measurements
      Crude 54/59 (91.5%) 49/59 (83.1%) 0.45 (0.15 – 1.42)
      Adjusted by site 0.46 (0.15 – 1.43)
      Adjusted by site and previous foot ulceration 0.43 (0.13 – 1.40)
Reduction of ≥1% of glycosylated hemoglobin
      Crude 20/58 (34.5%) 14/50 (28.0%) 0.74 (0.33 – 1.68)
      Adjusted by site 0.73 (0.32 – 1.67)
      Adjusted by site and previous foot ulceration 0.64 (0.28 – 1.51)
* HRs were calculated among the 169 participants that had at least one follow-up evaluation during the 18-month study period. ORs were calculated 
among the 158 participants that finished the 18-months follow-up and had complete data to analysis. All effect estimates were calculated using the 
thermometry-only arm as the reference group.





Among those who had a caregiver 
      Crude 6/31 (19.4) 7/31 (22.6) 1.11 (0.37 – 3.32)
      Adjusted by site and previous foot ulceration 0.43 (0.13 – 1.48)
Among those who did not had a caregiver 
      Crude 3/48 (6.3) 12/48 (25.0) 4.13 (1.16 – 14.63) 
      Adjusted by site and previous foot ulceration 3.34 (0.94 – 11.92)
* HRs were calculated among the 169 participants that had at least one follow-up evaluation during the 18-month study 
period. All effect estimates were calculated using the thermometry-only arm as the reference group
DFU, diabetic foot ulcer; CI, confidence interval; HR, hazard ratio.
the study period was intended to be 86 text messages and 76 
voice messages. The automated software system sent <50% of 
the intended SMS and voice messages to 1/86 (1.2%) of the 
participants, between 50–75% of the messages to 18/86 (20.9%) 
of the participants, and ≥75% of the messages to 67/86 (77.9%) 
of the participants. In contrast, text and voice messages 
received by the participants was <50% for 42/86 (48.8%) of the 
participants, and between 50% and 75% for 44/86 (51.2%) of 
the participants.
Preferences of SMS or voice messages. Among 101 interviewees 
(one participant did not answer), 42.6% preferred text 
messaging, whereas 57.4% preferred voice messages. Those 
who preferred voice messaging over SMS generally had that 
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      Use of TempStat™ in an illuminated area 8 (7.8%)
      Use of TempStat™ immediately after wake up 100 (97.1%)
      Use of the TemStat™ without socks and with 
warm feet 34 (33.0%)
      Use of the TempStat™ seated in a chair, with the 
feet on the device and with the hands in the knees 
applying a little pressure
46 (44.7%)
      Stay with the feet on the TempStat™ during 60 
seconds 68 (66.0%)
      Correct alarm sign identification 84 (81.6%)
      Daily registration in the logbook 54 (52.4%)
Logbook use 
      Participants using their logbooks 93 (90.3%) 
Nursing consultation 
      Report of communication with the study nurse 69 (66.9%) 
      Reason of the communication 
             Consultation about TempStat™ use 1 (1.5%)
             Alarm sign detection 5 (7.3%)
             Schedule consultation 63 (91.2)
      You consider that the nurse solved effectively 





      Always read the messages 27 (69.2%) 
      The messages help you a lot to improve your 
foot care 29 (74.4%) 
      The messages help you a lot to remember to 
use the device 27 (69.2%) 
Understanding of the messages
      Daily thermometer usage 37 (94.9%)
      Use of the TempStat™ during the morning 39 (100.0%)
      Correct identification of alarm sign 30 (76.9%)
      Correct actions if an alarm sign was detected 30 (76.9%)
      Use of warm water to wash your feet 32 (82.1)
      Avoid utilization of tight shoes 39 (100%)
preference because they had difficulty reading text messages 
on the cell phone screen. Other participants with this prefer-
ence mentioned that they have quicker access to the information 
with a voice message. Those who preferred SMS for reminders 
cited the fact that SMS can be read at their convenience. Some 
mentioned that they prefer SMS because they don’t want to 
have to listen for phone calls and/or pay attention to their phone 
at certain times.
Some participants commented that regardless of the reminder 
system (SMS or voice messaging), it was necessary to receive 
help from other people to read or listen to the messages. Their 
children were most commonly cited as the people to whom the 
participants would turn for help.
Use of TempStat™. Some participants mentioned that they 
had some periods during which they did not use the device. 
Among the reasons provided were that the device had techni-
cal problems or because they did not have the logbook to record 
their measurements.
Suggestions. Among the suggestions to improve the device 
and its use, technical comments were the most common. Par-
ticipants mentioned that they preferred a smaller size and lighter 
weight device. Furthermore, of the 8% of participants that had 
to replace the TempStat™ because of technical problems, some 
mentioned that an improved design could increase the lifetime 
of the device. Additionally, participants found the reinforce-
ment of the logbook and device utilization by the nurses to 
be very important, and some commented that more frequent 




This study was designed to compare the 18-month incidence 
of DFU between those receiving thermometry + mHealth 
reminders versus thermometry-only. The uptake of the thermom-
etry was high in this study, nearly 90% of the participants who 
returned the logbook had achieved ≥80% of the daily feet tem-
perature measurements. At baseline, we unexpectedly found 
a higher prevalence of previous foot ulceration in the interven-
tion arm, and the incidence of DFU was higher in this arm. In 
our study, conducted in a low-income setting, the addition of 
mHealth was not effective in reducing foot ulceration or increas-
ing adherence to thermometry after 18 months of follow-up. 
However, these results need to be interpreted with caution as 
the expected incidence rates of DFU used in our sample size 
calculations were not met and there was a higher rate of 
previous DFU in the intervention group. 
Comparison to previous studies
In our cohort, according to the process evaluation results, adher-
ence to temperature measurement was good, procedures about 
how to use the TempStat™ were regular (some steps have less 
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than 50% of correct answers) and correct alarm sign detec-
tion was good (81%). One previous study using thermometry 
found that 80% of participants who developed an ulcer did not 
comply with 50% of the temperature assessments, in con-
trast with the group that did not develop an ulcer, where 92% of 
participants recorded their foot temperatures at least half the time7.
Also, in our results, 41% (44/108) of the study participants 
recorded alarm signs for two consecutive days in their 
logbooks, and we only have data from 9/44 (20%) that had a 
record of reporting an alarm sign to the study nurse. These figures 
do not consider those with alarm signs that did not seek nurse 
support or those who did report to the nurse but their report was 
not recorded. 
The low rate of ulceration occurrence in our study could be 
potentially explained by two factors. First, that the participants 
did follow the instructions to reduce physical activity when 
observing alarm signs, even when they were not for two con-
secutive days or if they did not seek or receive the feedback of 
the study nurse. This is because the recommendations about 
reducing foot pressure and physical activity were given at the 
beginning of the study (videos) and they were also printed 
in their logbooks. Secondly, it is possible that the frequent 
assessment of the participant by the study nurse, every two 
months, may have played a role among study participants, includ-
ing the control group.  These two could have contributed to the 
lack of effect of the mHealth component in reducing foot 
ulceration.
Health interventions using SMS for diabetes management have 
been found to be useful for improving self-efficacy and social 
support11, as well as clinical diabetes-related outcomes12. 
However, most of the mHealth studies were conducted in high-
income countries, with a young population and with outcomes 
related to HbA1c measurements or questionnaires, without 
evaluating patient important outcomes like mortality, complica-
tions or quality of life. Despite the perceived benefit of mHealth 
in the elderly population31, very few studies with this population 
have been conducted in LMICs. Our automatic system deliv-
ered >75% of the messages to two-thirds of the participants only 
and it did not have a human support component, factors that 
may have affected the effective engagement with the mHealth 
intervention32,33. For example, a previous study using tailored 
motivational phone calls followed by SMS in people with 
pre-hypertension found a larger effect on bodyweight and waist 
circumference reduction in participants that received ≥75% 
of the calls34. Additionally, our system was automatic and did not 
allow direct bilateral communication. In a previous qualitative 
study from Canada, conducted to explore the views of patients 
in using mHealth to monitor and prevent DFU35, patients 
expressed interest in a two-way communication system to facili-
tate sharing of medical data, scheduling appointments and 
using of alerts to get access to medical attention. Also, a recent 
publication, evaluating 17 systematic reviews of mHealth inter-
vention studies in diabetes and obesity36, showed that fewer than 
half of the studies included in 2 reviews (out of 7 systematic 
reviews that covered the topic) improved diabetes manage-
ment practices or medication adherence37,38, and recommend the 
use of valid measures for outcomes and rigorous study designs 
to improve their quality. Finally, compared to previous mHealth 
studies where the focus has been on laboratory parameters 
or questionnaires39,40, we measured the impact of mHealth on 
DFU, an outcome of patient importance.
Limitations and strengths
Our study has some limitations. At baseline, participants assigned 
to the intervention arm were at higher risk of DFU, and the 
ulceration rate observed in the study was lower than expected. 
Together these reduced the accrual of sufficient DFU events 
despite extending the study from 12 to 18 months. Also, we 
did not collect information about the duration since the most 
recent wound healed. Recent research suggests ~10% of wounds 
recur within a month and 40% within a year of entering diabetic 
foot remission. Also, adherence to foot temperature measure-
ments was self-reported, and the adherence to the recommen-
dations of the reduction of physical activity was not recorded, 
not being able to characterise certain behaviours of direct rel-
evance to our DFU outcome. Our sample size calculations, 
which were made with an absolute change in DFU of 21% 
between the intervention and the control arm (9% vs 30%), using 
data derived from studies in high income countries, were differ-
ent from the incidence of DFU observed in our trial. Hence, 
it is possible that our study was underpowered to detect the 
expected effects. Finally, it is possible that those who did not 
return the logbook (~30%), where alarm signs were to be recorded, 
may be less conscientious about foot temperature measure-
ments and thus may have had lower rates of adherence to the 
thermometry.
The study also has some strengths; namely, it is a practical and 
pragmatic trial, well protected from bias, measuring an out-
come of importance to patients and inclusive of low-income 
patients over 60 years-old attending public hospitals in a 
middle-income country.
Relevance to public health
The experience of introducing a device to engage with self-
care behaviors for the prevention of DFU in a LMIC setting 
showed good adherence rates in both study arms, nearly reach-
ing 90%, signaling that mHealth had little room to further 
exert an impact. Future studies could pre-select participants 
with low adherence and explore if mHealth appears as a good 
supplement to prevent DFU.
Maintaining such DFU prevention efforts in routine clinical set-
tings may be difficult to sustain, yet this study demonstrates 
that adequate promotion of foot care can be achieved.
Conclusions
In this randomized trial, conducted in a LMIC setting, the 
uptake of the foot thermometry for the prevention of foot ulcers 
was 87% in the intervention and control groups, and the addi-
tion of mHealth was not effective in reducing foot ulceration or 
increasing adherence to thermometry after 18 months of 
follow-up. However, these results need to be interpreted with 
caution as the expected rates of DFU used in our sample size 
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calculations were not met and there was a higher rate of previous 
DFU in the intervention group.
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The manuscript submitted by Lazo-Porras et al. entitled “Foot thermometry with mHealth-based 
supplementation to prevent diabetic foot ulcers: A randomized controlled trial” is a well performed 
clinical study with published study protocol and enormous effort to ensure proper sampling of 
data. 
 
The main finding of the study is reported as a negative outcome finding: mHealth does not add to 
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the adherence of the patients at risk for diabetic foot ulceration to perform daily thermometry. 
There may be numerous interpretations and reasons for this negative result, which at first sight 
surprises and is counterintuitive to the general field. 
 
As referee I ask myself whether this is unexpected or whether there is an outlying explanation. 
The study protocol states: “Periodic assessments of the participants involving a general checkup 
and lower extremity evaluation was conducted every two months by the nurse evaluator.” Thus 
every participant was seen at least every second month by the nurse practitioner and the 
conversations within this assessment may be more important than the messages (either voice or 
text messages). What was the duration of the consultations? Was it standardized? It is my 
impression that these contacts may have skewed the results markedly and these effects have not 
been tested, as far as I understand the study. 
 
Another important aspect may be that the alarms have not been analyzed in their consequences. 
Have there been additional contacts to the study centre? Have these been recorded? How may a 
bias been excluded. 
 
In addition there is an unfortunate bias due to more DFU in the intervention group which makes it 
difficult to draw solid conclusions. 
 
The statements regarding the effectiveness of mHealth should be weakened markedly given the 
limitations and shortcomings of the study. These should therefore be stated in the respective 
chapters (abstract, discussion,conclusions).
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
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I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 01 Jul 2020
Maria Lazo-Porras, Universidad Peruana Cayetano Heredia, Lima, Peru 
1. The manuscript submitted by Lazo-Porras et al. entitled “Foot thermometry with mHealth-
based supplementation to prevent diabetic foot ulcers: A randomized controlled trial” is a 
well performed clinical study with published study protocol and enormous effort to ensure 
proper sampling of data.  
 
Response: We very much appreciate your comment. Thank you.  
  
2. The main finding of the study is reported as a negative outcome finding: mHealth does 
not add to the adherence of the patients at risk for diabetic foot ulceration to perform daily 
thermometry. There may be numerous interpretations and reasons for this negative result, 
which at first sight surprises and is counterintuitive to the general field.  
As referee I ask myself whether this is unexpected or whether there is an outlying 
explanation. The study protocol states: “Periodic assessments of the participants involving a 
general checkup and lower extremity evaluation was conducted every two months by the 
nurse evaluator.” Thus every participant was seen at least every second month by the nurse 
practitioner and the conversations within this assessment may be more important than the 
messages (either voice or text messages). What was the duration of the consultations? Was 
it standardized? It is my impression that these contacts may have skewed the results 
markedly and these effects have not been tested, as far as I understand the study. 
 
Response: The reviewer raises an important point related to the frequency of contacts 
between the study participants and the health system, which may help understanding 
the negative effects of our intervention. Prior to the study, we do not have any 
information about the participant’s frequency of contact with the health system. In 
principle, as part of the existing usual care, patients may be asked to visit their doctor 
every three months and whether or not they meet that criteria may have been 
affected by a variety of reasons, e.g. distance, transportation, availability of an 
appointment, costs, etc.  So, yes, we concur with the observation that our study 
promoted more frequent visits to the health system than usual care, and this may 
have had a role in the prevention of foot ulceration.   
  
Also, we did not collect the duration of the follow-up visit but the assessment included 
a questionnaire about medication, use of shoes and/or insoles, presence of a 
caregiver, blood pressure measurement and foot evaluation. These interactions could 
have impact the study findings skewed the results markedly.   We added the following 
in the manuscript: 
 
 “The low rate of ulceration occurrence in our study could be potentially explained by two 
factors. First, that the participants did follow the instructions to reduce physical activity 
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when observing alarm signs, even when they were not for two consecutive days or if they 
did not seek or receive the feedback of the study nurse. This is because the 
recommendations about reducing foot pressure and physical activity were given at the 
beginning of the study (videos) and they were also printed in their logbooks. Secondly, it is 
possible that the frequent assessment of the participant by the study nurse, every two 
months, may have played a role among study participants, including the control group.  
These two could have contributed to the lack of effect of the mHealth component in 
reducing foot ulceration.” 
 
3. Another important aspect may be that the alarms have not been analyzed in their 
consequences. Have there been additional contacts to the study centre? Have these been 
recorded? How may a bias been excluded?  
 
Response: Information about the alarms reported to the study nurse was low. 
However, we do not have reports about additional contacts with the study sites. What 
we know is that some participants maintained their usual care appointments with 
their endocrinologists.  
  
4. In addition there is an unfortunate bias due to more DFU in the intervention group which 
makes it difficult to draw solid conclusions.  
 
Response: This is true, and we concur. For that reason, we already discuss this as a 
limitation of the study. 
  
5. The statements regarding the effectiveness of mHealth should be weakened markedly 
given the limitations and shortcomings of the study. These should therefore be stated in the 
respective chapters (abstract, discussion, conclusions).  
 
Response: Yes. This is correct. We have refined our conclusions (see Reviewer 1, 
response #2).  
Competing Interests: No competing interests were disclosed.
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© 2020 Ena J. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
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Javier Ena  
Hospital Marina Baixa, Alicante, Spain 
This is a well-conducted randomized clinical trial including 172 patients at risk of 
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DFU. Randomization technique was well carried out, but unfortunately, there was a greater risk for 
DFU in the intervention group due to a greater proportion of previous DFU. The intervention was 
well explained. However, the authors did not assess patients' adherence to recommendations to 
reduce daily exercise. 
Finally, the clinical trial did not show the advantage of using foot thermometry and mHealth 
supplementation to reduce DFU. 
A big caveat of the study is the sample size. According to my estimates, the number of patients 
included in the clinical trial was too small to show a possible benefit of the intervention. Taking 
into account a risk of DFU in the control group of 24%, a reduction of 50% in the risk of DFU in the 
intervention group with a power of 80% and a two-sided alfa error of 5%, the sample size called 
for 159 patients per arm (Fleiss estimation).  
In summary, it is not clear whether foot thermometry with mHealth-based supplementation is 
useful or not to prevent DFU.
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Diabetes complications
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 01 Jul 2020
Maria Lazo-Porras, Universidad Peruana Cayetano Heredia, Lima, Peru 
1. This is a well-conducted randomized clinical trial including 172 patients at risk of 
DFU. Randomization technique was well carried out, but unfortunately, there was a greater 
risk for DFU in the intervention group due to a greater proportion of previous DFU. The 
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intervention was well explained. However, the authors did not assess patients' adherence to 
recommendations to reduce daily exercise. 
Finally, the clinical trial did not show the advantage of using foot thermometry and mHealth 
supplementation to reduce DFU.  
 
Response: Thank you for your feedback. Yes, we did not measure adherence to the 
recommendations of the reduction of daily physical activity and for that reason we 
are adding that as a limitation:  
“Also, adherence to measurements was self-reported, and the adherence to the 
recommendations of the reduction of physical activity was not recorded, not being able to 
characterise certain behaviours of direct relevance to our DFU outcome." 
  
2. A big caveat of the study is the sample size. According to my estimates, the number of 
patients included in the clinical trial was too small to show a possible benefit of the 
intervention. Taking into account a risk of DFU in the control group of 24%, a reduction of 
50% in the risk of DFU in the intervention group with a power of 80% and a two-sided alfa 
error of 5%, the sample size called for 159 patients per arm (Fleiss estimation).   
 
Response: Thank you for your comment. We estimated the sample size with an 
absolute change of 21% between the intervention arm and the control arm (9% vs 
30%). However, these data came from previous results in high income countries and 
differs from the incidence of diabetic foot ulcer results observed in our trial.  We 
added the following information in the manuscript. 
  
Our sample size calculations, which were made with an absolute change of 21% between 
the intervention and the control arm (9% vs 30%), using data derived from studies in high 
income countries, were different from the incidence of DFU results observed in our trial. 
Hence, it is possible that our study was underpowered to detect the expected effects” 
  
3. In summary, it is not clear whether foot thermometry with mHealth-based 
supplementation is useful or not to prevent DFU. 
 
Response: This is correct. We have refined our conclusions (see Reviewer 1, response 
#2).  
Competing Interests: No competing interests were disclosed.
Reviewer Report 17 April 2020
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© 2020 van Netten J. This is an open access peer review report distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
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Jaap J. van Netten   
Department of Rehabilitation, Amsterdam Movement Sciences, Amsterdam UMC, University of 
Amsterdam, Amsterdam, The Netherlands 
This is a well-performed RCT, with clear protocol published in advance, and following general rules 
for RCTs. The manuscript is easy to read, has clear description of results, and adds to the body of 
knowledge in the field of diabetic foot disease. 
I have some comments to improve understanding and interpretation of the findings, and I think 
the authors can be more clear in describing the negative results of the intervention. I will discuss 
these per section. 
  
Abstract: 
The conclusion from the abstract is not a conclusion and not informative. This should be 
something along the lines of the primary outcome and primary research question, such as 
“mHealth is not effective in reducing foot ulceration or increasing adherence to thermometry”. 
 
Introduction: 
It is stated that “3 trials have been performed on thermometry”. The fourth trial that is available 
on this topic should also be mentioned here (Skafjeld et al.)1, and perhaps some of the meta-
analyses as well (e.g. Crawford et al, 2019)2. 
 
Importance of interventions to improve adherence to diabetic foot self-care is also described in 
various other papers, such as the IWGDF systematic review on preventative interventions and the 
review on modifiable interventions (Van Netten et al. 2020a and 2020b)3,4, or papers on adherence 
in relation to diabetic foot disease (e.g. Price 2016)5. The introduction would improve in depth if 
importance of adhering to these aspects of diabetic foot self-care would also be included, rather 
than focusing only on thermometry. 
 
Methods: 
It is stated that the previous trials only included IWGDF3, but that is not correct. At least one 
temperature trial (Lavery et al.)6 included also IWGDF2 patients. 
 
How was education at baseline delivered? Verbal, written, pictures, videos? 
 
The TempStat is used, but no information is provided in the methods about the validity and 
reliability of this instrument. 
 
Was there any way to assess if alerts appeared, other than the logbook? Did authors test this 
instrument in advance? 
 
From the sentence: “In the intervention arm, additional to the TempStat™ participants received the 
mHealth component (two reminder messages and six foot-care promotion messages) during the 
18-month study period via both SMS and voice messaging.” it reads as if these messages were 
only sent 8 times throughout the entire period. However, in a subsequent paragraph it’s clear they 
were sent weekly. Please rephrase this sentence to make sure it reflects what happened. 
 
It is stated that alarms were not analysed “because of their low frequency.” However, with 28 
ulcers developed, one would expect a fair amount of warnings (if the skin indeed heats up before 
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it breaks down). Can the authors explain why alarms were of such low frequency? 
 
Is it correct that the blinded evaluator was evaluating the ulcers in real-life, not via photos? i.e.: 
patients could tell which arm they were in, albeit inadvertently? 
 
Randomization via envelopes is not considered independent anymore, since these can be (easily) 
manipulated. Please describe what was done to prevent this. 
 
Results: 
Flowchart: add “n=” in the last box (e.g. n=59), to avoid that readers may think that this is an 
outcome (because HbA1c of 50 is a potential finding). 
 
Flowchart: are there any reasons for lost to follow-up? 
 
Baseline: any information on comorbidities, such as cardiac disease? 
 
Baseline: can authors provide some additional info on foot deformities? What sort of deformities 
were found, how were these assessed? 
 
I miss information on footwear and other preventative self-care of the patients throughout the 
trial. 
 
Why were no multivariate analyses done? 
 
Discussion 
Main findings: the actual main finding is somewhat obscured in this paragraph. It is described as 
“At baseline, we unexpectedly found a higher prevalence of previous foot ulceration in the 
intervention arm, and the incidence of DFU was higher in this arm.”. However, these are two 
separate findings. The current presentation suggests causality, but that’s not the case. Because it 
is clear in the results that even a subanalysis in patients with a previous DFU shows higher 
incidence during the study in the intervention group (23% vs 30%). Authors should be crystal clear 
in their main finding here, see also my comment concerning the abstract. The finding is simple: 
mHealth does not help. 
 
In the “comparison to previous studies”, the actual findings are not discussed. Part of this section 
is now a simple repetition of the introduction, the other parts fail to acknowledge the negative 
findings of the current study. Why does mHealth appear to be beneficial in other studies, but not 
in this study? That is what should be reflected on. 
 
I miss any discussion about the comment that alarms were not evaluated because of their low 
frequency. That implies that thermometry is not useful in ulcer prevention. This should be 
discussed in depth. 
 
Ulcer incidence in patients with a previous ulcer is 27.8%, which is somewhat lower than other 
studies. Can this be attributed to the thermometer? And if so, how, if the thermometer never gives 
an alarm? Or is this because usual care is really good? 
 
I miss discussion of the reliability and validity of the instrument, or the lack of knowledge thereof. 
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In the limitation section, I miss acknowledging limitations in randomization (done with envelopes) 




Authors have a more clear conclusion in this section (first sentence). That is what should be used 
in the abstract and discussion. 
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Reviewer Expertise: Diabetic foot disease, biomechanics, human movement sciences.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 01 Jul 2020
Maria Lazo-Porras, Universidad Peruana Cayetano Heredia, Lima, Peru 
1. This is a well-performed RCT, with clear protocol published in advance, and following 
general rules for RCTs. The manuscript is easy to read, has clear description of results, and 
adds to the body of knowledge in the field of diabetic foot disease.  
 
Response: Thank you for your positive feedback. 
  
2. I have some comments to improve understanding and interpretation of the findings, and 
I think the authors can be more clear in describing the negative results of the intervention. I 
will discuss these per section.  
 
Abstract: 
The conclusion from the abstract is not a conclusion and not informative. This should be 
something along the lines of the primary outcome and primary research question, such as 
“mHealth is not effective in reducing foot ulceration or increasing adherence to 
thermometry”. 
 
Response: Thank you for your suggestion, we have added a paragraph based on your 
recommendation but also including suggestions of the other two reviewers (see 
reviewer 2 comments #2 and #3, and reviewer 3 comments #2, #5 and #6). The 
Abstract’s conclusion now reads: 
 
“In our study, conducted in a low-income setting, the addition of mHealth to foot 
thermometry was not effective in reducing foot ulceration. Importantly, there was a higher 
rate of previous DFU in the intervention group, the adherence to thermometry was high, 




It is stated that “3 trials have been performed on thermometry”. The fourth trial that is 
available on this topic should also be mentioned here (Skafjeld et al.)1, and perhaps some of 
the meta-analyses as well (e.g. Crawford et al, 2019)2. 
  
Response: We agree with your comment and we have added these articles in our 
introduction section. 
 
“Three previous clinical trials and one systematic review have found that the use of 
thermometry reduced DFU incidence four- to ten-fold among individuals with diabetes at 
high-risk of developing a DFU 1. Additionally, one study found that the addition of 
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counselling to promote self-monitoring of skin temperature to standard care is feasible 2.” 
  
4. Importance of interventions to improve adherence to diabetic foot self-care is also 
described in various other papers, such as the IWGDF systematic review on preventative 
interventions and the review on modifiable interventions (Van Netten et al. 2020a and 
2020b)3,4, or papers on adherence in relation to diabetic foot disease (e.g. Price 2016)5. The 
introduction would improve in depth if importance of adhering to these aspects of diabetic 
foot self-care would also be included, rather than focusing only on thermometry. 
  
Response: Thank you for your suggestion. We have expanded our introduction to 
include evidence about the importance of foot care. 
  
“Other approaches that could prevent foot ulcers include patient’s foot self-care behaviour, 
annual foot evaluations, knowledge about diabetic foot in health care workers, and 
therapeutic footwear 3. Also, in order to prevent recurrent ulcers, it is important to 
consider the integration or combination of these approaches 4." 
 
5. Methods: 
It is stated that the previous trials only included IWGDF3, but that is not correct. At least one 
temperature trial (Lavery et al.)6 included also IWGDF2 patients. 
  
Response: Yes, that it is true. We have changed the information accordingly.  
 
“Our eligibility criteria used IWGDF categories and included people with diabetes at risk of 
ulceration group 2 and 3. In so doing, rather than focusing only on those at the highest risk 
for ulceration (IWGDF group 3) we wanted to pursue a pragmatic approach for the 
prevention of DFU among people with diabetes, thus including also those participants from 
the IWGDF group 2 category. All previous studies included mostly participants from IWGDF 
group 3, and only one clinical trial included group 2 patients.” 
  
6. How was education at baseline delivered? Verbal, written, pictures, videos? 
 
Response: We used videos to educate participants about foot care. We have clarified 
this information in the article.  
 
“At the initiation visit, all participants received education about foot care, i.e. etiology and 
risk factors for the development of neuropathy and ulcers, as well as recommendations for 
foot care practices and early signs of ulceration; and instructions for the use of the 
TempStat™ device (see Extended data). This foot care education was done through three 
videos that were validated by physicians and patients with type 2 diabetes mellitus. The 
first two videos lasted 8 and 6 minutes and they were related to foot care, whereas the 
third video lasted 6 minutes and presented the instructions on the use of the TempStat™ 
device. The three videos were in Spanish and were showed once at the initiation visit.”  
 
7. The TempStat is used, but no information is provided in the methods about the validity 
and reliability of this instrument.  
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Response:  We included some of this information in our protocol, already published 5. 
But we also think that it is a good suggestion and we decided to include this in the 
article. 
  
“Frykberg et al. 6 showed that TempStat™ can detect alarm signs, represented by a yellow 
color change, and the results positively correlate to temperature findings of infrared 
thermometer, the gold standard of thermometry devices. Another study found that the 
device identified 74% of serious foot problems 7 " 
 
8. Was there any way to assess if alerts appeared, other than the logbook? Did authors test 
this instrument in advance?  
 
Response: We did not have another method to assess this during the study, other than 
using the logbook. Before embarking on this strategy, we piloted the TempStat™ and 
logbook with 10 patients, for two weeks, to know if the participants understood the 
instructions of the video about how to use the TempStat™ and if they recorded 
adequately their information in the logbook. We verified that they had understood 
the instructions and completed the logbook correctly. We know that this is not the 
best method because of the information being self-reported but, given the pragmatic 
nature of the study, it was the most feasible approach in the study setting where our 
study was carried out. During the conduction of the study, between 2015 and 2016, 
many patients did not yet have a smartphone or access to other technologies to ask 
them to send us an objective image of the TempStat™. We include this information as 
a limitation in the discussion. 
  
 “Also, adherence to measurements was self-reported, which potentially introduced 
bias.and the adherence to the recommendations of the reduction of physical activity was 
not recorded, not being able to characterise certain behaviours of direct relevance to our 
DFU outcome.” 
“Finally, it is possible that those who did not return the logbook (~30%), where alarm signs 
were to be recorded, may be less conscientious about foot temperature measurements and 
thus may have had lower rates of adherence to the thermometry.” 
  
9. From the sentence: “In the intervention arm, additional to the TempStat™ participants 
received the mHealth component (two reminder messages and six foot-care promotion 
messages) during the 18-month study period via both SMS and voice messaging.” it reads 
as if these messages were only sent 8 times throughout the entire period. However, in a 
subsequent paragraph it’s clear they were sent weekly. Please rephrase this sentence to 
make sure it reflects what happened.  
 
Response: Thank you for your comment. We have clarified this section because the 
messages were sent weekly. 
  
“In the intervention arm, in addition to the TempStat™, participants received the mHealth 
component weekly (two reminder messages and six foot-care promotion messages each 
week) for the 18-month study period via both SMS and voice messaging.” 
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10. It is stated that alarms were not analysed “because of their low frequency.” However, 
with 28 ulcers developed, one would expect a fair amount of warnings (if the skin indeed 
heats up before it breaks down). Can the authors explain why alarms were of such low 
frequency?  
 
Response: The report of the alarms to the nurses was low, but records from the 
logbooks showed that 41% of the participants reported an alarm sign (we only 
considered an alarm sign if it was reported during 2 or more consecutive days). 
Additionally, 67% of the participants that presented an ulcer reported an alarm sign in 
the logbook.  We have now included the following information in the manuscript  
  
“Also, we found that 41% of the participants recorded an alarm sign in their logbooks. 
Additionally, 67% of the participants that presented an ulcer also reported an alarm sign in 
their logbook.” 
  
11. Is it correct that the blinded evaluator was evaluating the ulcers in real-life, not via 
photos? i.e.: patients could tell which arm they were in, albeit inadvertently?  
 
Response: The blinded evaluator saw the patient every two months, and if an ulcer 
was developed in this period the patient could also attend to an additional visit to the 
hospital to receive care and to be evaluated by the blinded evaluator. Participants 
were recommended not to mention their study arm (thermometry + mHealth vs. 
thermometry only). We did not receive any report of the blinded nurses related to a 
protocol deviation. 
  
12. Randomization via envelopes is not considered independent anymore, since these can 
be (easily) manipulated. Please describe what was done to prevent this.  
 
Response: The procedure was as follow, the patient received a code in the hospital 
when it was recruited by the study nurse, then the study coordinator opened the 
envelop containing details of the random allocation of the participant to the 
intervention or the control group. So, it was not possible to the study nurse to know 
the allocation of the participant, and it was not possible to the study coordinator to 
evaluate the participant and give the code to him/her. We are providing more details 
in our manuscript: 
  
“We conducted stratification using the hospital site as a single stratum and blocks of 6 to 
generate a random allocation sequence. Sealed envelopes with codes to randomize 
participants were used. An independent researcher prepared the envelopes, and the study 
nurses assigned the codes to each of the enrolled participants. Separately, the study 
coordinator was responsible for opening the envelopes and informing participants about 
their intervention or control allocation as per the random list. The nurse/independent 




13. Flowchart: add “n=” in the last box (e.g. n=59), to avoid that readers may think that this is 
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an outcome (because HbA1c of 50 is a potential finding).  
 
Response: Thank you for your suggestion, we added the “n=” 
  
14. Flowchart: are there any reasons for lost to follow-up?  
 
Response: In our study, lost to follow-up were study participants where re-contact was 
not possible: some of them migrated back to their place of origin, and in other cases it 
was not possible to find the addresses provided, or the participant did not answer the 
phone calls. We have added these details in the manuscript: 
  
“Reasons for lost to follow-up included migration back to the participant’s place of origin, 
wrong/incomplete addresses provided, or the participant did not answer the contact phone 
calls.” 
  
15. Baseline: any information on comorbidities, such as cardiac disease?  
 
Response: Yes, that information is already provided in Table 1.  
 
16. Baseline: can authors provide some additional info on foot deformities? What sort of 
deformities were found, how were these assessed?  
 
Response: The study nurses evaluated the deformities during the screening 
assessment, and we only considered 4 types of deformities: claw foot (40.5%), 
prominent metatarsal head (33.3%), Charcot foot (9.5%), and hammer toe (19.1%). This 
information is provided in the baseline characteristics section.   
  
17. I miss information on footwear and other preventative self-care of the patients 
throughout the trial.  
 
Response: Less than 10% of the participants reported using orthopedic shoes or 
insoles. This information is available in Table 1. 
 
18. Why were no multivariate analyses done?  
 





19. Main findings: the actual main finding is somewhat obscured in this paragraph. It is 
described as “At baseline, we unexpectedly found a higher prevalence of previous foot 
ulceration in the intervention arm, and the incidence of DFU was higher in this arm.” 
However, these are two separate findings. The current presentation suggests causality, but 
that’s not the case. Because it is clear in the results that even a subanalysis in patients with a 
previous DFU shows higher incidence during the study in the intervention group (23% vs 
30%). Authors should be crystal clear in their main finding here, see also my comment 
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concerning the abstract. The finding is simple: mHealth does not help.  
 
Response: Thank you for your comment. Even when our study found that mHealth 
does not help, some study limitations could explain this finding. For that reason, we 
change our conclusion. We have edited our abstract conclusions (see response #2) and 
we have done the same in here.  
 
“In our study, conducted in a low-income setting, the addition of mHealth was not effective 
in reducing foot ulceration or increasing adherence to thermometry after 18 months of 
follow-up. However, these results need to be interpreted with caution as the expected rates 
of DFU used in our sample size calculations were not met and there was a higher rate of 
previous DFU in the intervention group.” 
 
20. In the “comparison to previous studies”, the actual findings are not discussed. Part of 
this section is now a simple repetition of the introduction, the other parts fail to 
acknowledge the negative findings of the current study. [Why does mHealth appear to be 
beneficial in other studies, but not in this study? That is what should be reflected on.  
 
Response: Thank you for your comment, some of the reasons that we cover in our 
discussion include:
Most previous studies in mHealth were conducted in high-income countries with 
mostly young populations. In contrast, our study was implemented in a low-
resource setting of a middle-income country with an elderly population.
○
Outcomes in previous studies were glycated hemoglobin measurements or 
questionnaires and scales of self-management. We used ulceration, a patient-
centered and clinically relevant outcome.
○
The automated software system used in our study to send messages did not 
have bilateral communication, it was one-way only, and some studies suggest 
that bilateral communication may be a preferred route among people with 
diabetes.
○
Finally, we are now including evidence from a recent systematic review of 




“A recent publication, evaluating 17 systematic reviews of mHealth intervention studies in 
diabetes and obesity 8, showed that fewer than half of the studies included in 2 reviews 
(out of 7 systematic reviews that covered the topic) improved diabetes management 
practices or medication adherence 9, 10 , and recommend the use of valid measures for 
outcomes and rigorous study designs to improve their quality”.  
 
21. I miss any discussion about the comment that alarms were not evaluated because of 
their low frequency. That implies that thermometry is not useful in ulcer prevention. This 
should be discussed in depth.  
 
Response: As we clarified in response #10, the reporting of alarm signs to the study 
nurse was low, but information registered in the logbooks showed reports of alarm 
signs of up to 41%. We have now added this information in the results section (see 
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response #10). Also, in the discussion we now have added the following statement:  
 
“Also, in our results, 41% (44/108) of the study participants recorded alarm signs for two 
consecutive days in their logbooks, and we only have data from 9/44 (20%) that had a 
record of reporting an alarm sign to the study nurse. These figures do not consider those 
with alarm signs that did not seek nurse support or those who did report to the nurse but 
their report was not recorded.”  
 
“The low rate of ulceration occurrence in our study could be potentially explained by two 
factors. First, that the participants did follow the instructions to reduce physical activity 
when observing alarm signs, even when they were not for two consecutive days or if they 
did not seek or receive the feedback of the study nurse. This is because the 
recommendations about reducing foot pressure and physical activity were given at the 
beginning of the study (videos) and they were also printed in their logbooks. Secondly, …” 
  
22. Ulcer incidence in patients with a previous ulcer is 27.8%, which is somewhat lower than 
other studies. Can this be attributed to the thermometer? And if so, how, if the 
thermometer never gives an alarm? Or is this because usual care is really good?  
 
Response: We acknowledge that ulcer incidence was somewhat low in our study and 
perhaps the thermometry, provided to all study participants, may have been a 
contributing factor to the low incidence of ulcers observed. In our study, patients 
were explained about how to use the TempStat™ and one of the recommendations 
provided was to reduce physical activity if they find an alarm sign. Another practical 
feature was that the thermometer had a mirror in the middle of the two pads allowing 
the observation of the foot soles. So, it is possible that the thermometer alone was an 
effective intervention, in our population, for the prevention of the incidence of ulcers. 
Foot care among people with type 2 diabetes in Peru is very low, which also indicates 
need to enhance current standards of care in terms of prevention of foot ulcers.  
  
23. I miss discussion of the reliability and validity of the instrument, or the lack of 
knowledge thereof. 
 
Response: As mentioned before in the response #7, we have now added information 
about the reliability and validity of the TempStat™ 
  
24. In the limitation section, I miss acknowledging limitations in randomization (done with 
envelopes) and blinding (outcome assessor could be unblinded by patients). See comments 
in method section.  
 
Response: We have already explained our randomization procedures (see response 
#12). Also, according to CONSORT guidelines, sealed envelopes are an acceptable 
method for randomization, and their explanation is as follow: “Enclosing assignments 
in sequentially numbered, opaque, sealed envelopes can be a good allocation 
concealment mechanism if it is developed and monitored diligently. This method can 
be corrupted, however, particularly if it is poorly executed. Investigators should 
ensure that the envelopes are opaque when held to the light, and opened sequentially 
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25. Authors have a more clear conclusion in this section (first sentence). That is what should 
be used in the abstract and discussion.  
 
Response: Yes, noted. We have edited our conclusion in the abstract (see response #2), 
and also edited our conclusion in the discussion based in the three reviewer’s 
suggestions, which now reads: 
 
“In this randomized trial, conducted in a LMIC setting, the uptake of the foot thermometry 
for the prevention of foot ulcers was 87% in the intervention and control groups, and the 
addition of mHealth was not effective in reducing foot ulceration or increasing adherence 
to thermometry after 18 months of follow-up. However, these results need to be 
interpreted with caution as the expected rates of DFU used in our sample size calculations 
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